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Background: Hypertrophic cardiomyopathy (HCM) is a myocardial disorder characterised by left ventricular
hypertrophy (LVH) in the absence of another cardiac or systemic disease capable of producing the magnitude of
LVH evident. HCM causes variable symptoms and is one of the leading causes of sudden cardiac death (SCD) in
young adults. While various phenotypic features of HCM among monozygotic twin pairs are not uncommonly
reported, occurrence of synchronous cardiac arrest among them is not known from literature.
Case presentation: We present a case of monozygotic twins with HCM who both had a cardiac arrest post
physical exertion in 63rd year of their lives.
Conclusion: This case highlights potential genetics predisposition of cardiac arrest in patients with HCM despite
having different phenotypic expression. SCD may be the only manifestation of patients with HCM. Decision of
implantable cardioverter-defibrillator (ICD) placement for primary prevention of SCD should be based on the
recommended guidelines, clinical judgment and patient’s preference.
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HCM is a myocardial disorder characterised by left ven-
tricular hypertrophy (LVH) in the absence of another
cardiac or systemic disease capable of producing the
magnitude of LVH evident. It is a genetic disorder, most
commonly caused by autosomal dominant mutations in
genes encoding protein components of sarcomere and
myofilaments [1], characterised by variable disease ex-
pression and age-related penetrance [2]. HCM causes
variable symptoms and is one of the leading causes of
SCD in young adults [3]. We present a case of monozy-
gotic twins with HCM who both had a cardiac arrest
post physical exertion in 63rd year of their lives.
Case presentation
A 62-year-old man presented with first episode of un-
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unless otherwise stated.tachyarrhythmia with underlying HCM. Fortunately
he survived the episode as he had an implantable
cardioverter-defibrillator (ICD) inserted two months
ago, after his monozygotic twin brother suffered a
fatal cardiac arrest.
Patient’s twin brother, in whom the basis of monozy-
gosity was established by history taken from our pa-
tient, was diagnosed with HCM 30 years ago following
a routine work-related medical check-up. He was a
physically active person, with no known risk factors
for ischaemic heart disease (IHD) and no regular
medication. He had an excellent exercise tolerance in-
cluding regular strenuous activities like surfing and
skiing. He did not have any prior history of syncope or
presyncope, or any family history of sudden death. His
echocardiogram done 4 weeks prior to event showed
normal left ventricular (LV) size and function, marked
asymmetric septal hypertrophy of 1.9 cm and no evi-
dence of left ventricular outflow tract (LVOT) ob-
struction. A 24-hour holter monitoring done 4 years
ago showed no evidence of non-sustained ventricularis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
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cardiogram done 9 years ago showed no inducible
LVOT gradient with a normal blood pressure re-
sponse. He suffered sudden cardiac death at the age of
62 when he collapsed immediately after completing
few laps of swimming with pre-warning signs of
dizziness.
Our patient was also known to have asymptomatic
HCM as part of family screening 30 years ago. Follow-
ing his brother’s death, he underwent an elective ICD
implantation a week later. After two months, he pre-
sented to the hospital with an unwitnessed syncopal
episode lasting one minute, preceded by pre-warning
signs of dizziness while at work on a ladder. He
regained his consciousness afterwards and rang an am-
bulance. The ECG revealed a sinus rhythm with nor-
mal axis (Figure 1). Interrogation of ICD revealed 15
episodes of NSVT with a rate of 140 beats/min,
followed by malignant ventricular tachyarrhythmia for
12 seconds, terminated successfully by a single shock
(Figure 2).
Like his brother he was previously well with no sig-
nificant cardiovascular risk factors for IHD and no
regular medication. His physical examination was un-
remarkable with vital parameters within normal
limits. His initial troponin was 0.06 (NR <0.04) with
no serial increment. An urgent angiogram revealed no
significant coronary artery disease. An echocardio-
gram two months before the incident showed normal
LV size and systolic function, asymmetric septal
hypertrophy of 2.8 cm, and no evidence of LVOT ob-
struction. His previous 24-hour holter monitoring
done three years ago had shown no evidence of NSVT.
He did not undergo any exercise test in the past
8 years.Figure 1 Patient’s 12-lead ECG on arrival to hospital showing sinus rhHe was admitted to intensive care unit (ICU) with car-
diac monitoring and was commenced on sotalol. There
was no further ventricular tachyarrhythmias noted on
telemetry and he was discharged on day 4 with out-
patient follow up.
Differential diagnosis
As patient’s brother did not undergo a post-mortem
examination, the exact cause of death could not be
ascertained. Differential diagnosis to consider apart from
sudden cardiac death secondary to HCM would include
coronary artery disease or pulmonary embolism. For our
patient, ventricular tachyarrhythmia arising from a
proarrhythmic impulse from the recently implanted ICD
could be an alternative explanation for his ventricular
arrhythmia episode.
Discussion
The exact mechanism of SCD in HCM is not known,
but is thought to be secondary to malignant ventricular
tachyarrhymias arising from abnormal myocardial fibres
[4]. While various phenotypic features of HCM among
monozygotic twin pairs are not uncommonly reported
[5], occurrence of synchronous cardiac arrest among
them is not known from literature.
As SCD may be the only manifestation of patients
with HCM, it is important to distinguish features of
HCM, which are associated with high risk of SCD. The
consensus document of American College of Cardi-
ology Foundation and American Heart Association
classified these risk factors as established risk markers
and potential SCD risk modifiers [6]. Established risk
markers include previous cardiac arrest (ventricular
fibrillation; VF) or sustained VT, family history of SCD
at age < 50, unexplained syncope, abnormal exerciseythm.
Figure 2 Interrogation of implantable cardioverter-defibrillator (ICD). A. Rhythm strip showing ventricular tachyarrhythmia. B. Ventricular
tachyarrhythmia successfully terminated by the ICD shock.
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(Table 1). The potential risk modifiers include presence
of LVOT obstruction, LV apical aneurysm, late gadolin-
ium enhancement (LGE) in cardiac magnetic resonance
imaging (MRI) and high risk mutations. Furthermore, the
guidelines recommend risk stratification be performed
periodically every 12 to 24 months for patients with HCM
who have not undergone an ICD implantation (Class IIa).
Invasive electrophysiological study is not recommended in
accessing SCD risk in HCM [6].Table 1 Indications for ICD implantation in HCM patients to p
ICD Recommended
(Class I)
ICD Reasonable (Class IIa) ICD M
● Prior cardiac arrest ● Family history of sudden death in first
degree relative (age <50)
● No
mo
● Sustained VT ● LV wall thickness ≥ 30 mm Note
absen
● Recent unexplained syncope
Modified from Gersh BJ, Maron BJ, Bonow RO et al. 2011 ACCF/AHA Guideline for the
American College of Cardiology Foundation/American Heart Association Task Force on
(ICD = implantable cardioverter-defibrillator; HCM= hypertrophic cardiomyopathy; SCD
BP = blood pressure).Though currently available genetic testing is consid-
ered reasonable to identify first-degree relative at risk of
developing HCM [6], it has not been proven useful in
predicting clinical course and risk of SCD [7]. Family
members with similar genetic mutations may have en-
tirely different phenotypic expression [8]. While most
phenotype of HCM in monozygotic twins are concord-
ant, phenotype with discordant features has been re-
ported [9]. Our case report relates to twin brothers who
had varying severity of asymmetrical LV hypertrophy,revent SCD
ay be Useful (Class IIa)
n-sustained VT or abnormal BP response in presence of other SCD risk
difiers.
: Role of ICD is uncertain in non-sustained VT or abnormal BP response in
ce of other SCD risk modifiers (Class IIb)
Diagnosis and Treatment of Hypertrophic Cardiomyopathy: A Report of the
Practice Guidelines. Circulation. 2011;124: e783-e831.
= sudden cardiac death; VT = ventricular tachycardia; LV = left ventricle/ventricular;
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areas of Australia, and suffered cardiac arrest around the
same time in their lives. This highlights the potential
genetic predisposition of cardiac arrest in patients with
HCM despite having different phenotypic expression.
While it is likely to be a coincidence, the synchronous
timing of cardiac arrest does raise a question whether an
alternative explanation such as an underlying genetic
cause could account for such synchronous timing. This
however remains unlikely as lacks scientific evidence at
this stage, and if such genetic factor did exist, more
cases of synchronous cardiac arrests among siblings or
relatives would have been reported in literature.
Conclusion
This case highlights potential genetic predisposition of
cardiac arrest in patients with HCM despite having dif-
ferent phenotypic expression. SCD may be the only
manifestation of patients with HCM. Decision of ICD
placement for primary prevention of SCD should be
based on the recommended guidelines, clinical judgment
and patient’s preference.
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